The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.
Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be performed at every visit. Patients will be compensated for time and travel.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
6
10mg
placebo
Bernstein Allergy Group
Cincinnati, Ohio, United States
RECRUITINGDetermine whether montelukast is more effective than placebo at reducing the number of nasal eosinophils associated with NARES
Time frame: December 2008
Determine whether montelukast is more effective than placebo at reducing nasal symptom scores
Time frame: December 2008
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.